Tech Company Financing Transactions
OrsoBio Funding Round
OrsoBio closed a $60 million Series A funding round on 11/7/2023. Backers included Enavate Sciences, private investors and Longitude Capital Management.
Transaction Overview
Company Name
Announced On
11/7/2023
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to advance the development of its innovative four programs focused on obesity and associated metabolic disorders.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2671 Marshall Dr
Palo Alto, CA 94303
USA
Palo Alto, CA 94303
USA
Phone
Undisclosed
Website
Email Address
Overview
OrsoBio is a clinical-stage biopharmaceutical company that creates therapies for patients suffering from severe metabolic disorders such as diabetes, severe dyslipidemia, lipodystrophies, and others. OrsoBio is committed to restoring energy homeostasis in patients with severe metabolic disorders, in some cases, by targeting pathways relevant tomaintaining energy balance. OrsoBio revolutionizes the treatment of these disorders by addressing the underlying cause.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mani Subramanian
Co-Founder
Gans Ganapati
Browse more venture capital transactions:
Prev: 11/7/2023: Spill venture capital transaction
Next: 11/7/2023: Coperniq venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs